AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer
Pressmeddelanden • Nov 16, 2018 08:02 CET
AstraZeneca and MedImmune, today announced final overall survival results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care platinum-based chemotherapy in previously-untreated patients with Stage IV (metastatic)NSCLC.
Pressmeddelanden • Nov 13, 2018 08:01 CET
AstraZeneca has agreed to sell US rights to Synagis(palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.
US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review
Pressmeddelanden • Nov 12, 2018 08:07 CET
AstraZeneca and Merck & Co., Inc. US today announced that the US FDA has accepted a supplemental New Drug Application for Priority Review for the use of Lynparza tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial
Pressmeddelanden • Nov 10, 2018 22:48 CET
Fewer MACE events observed with Farxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier’s gangrene with Farxiga vs. placebo
Pressmeddelanden • Nov 08, 2018 08:02 CET
AstraZeneca återgår till tillväxt i produktförsäljningen; nya läkemedel och tillväxtmarknaderna leder vägen
Pressmeddelanden • Nov 06, 2018 08:02 CET
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), usedfor the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines.
The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018
Pressmeddelanden • Nov 01, 2018 08:02 CET
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III CV outcomes trial (CVOT) DECLARE-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company’s CVRM therapy area at the American Heart Association (AHA) Scientific Sessions, 10-12 November 2018, in Chicago, Illinois, USA.
Pressmeddelanden • Okt 30, 2018 08:03 CET
AstraZeneca has agreed to divest the prescription medicine rights to Nexium(esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory
Phase III HARMONIZE Global trial of Lokelma confirms efficacy in maintaining normal potassium levels in Asian patients with hyperkalaemia
Pressmeddelanden • Okt 25, 2018 19:03 CEST
AstraZeneca today presented the results from the HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea, Taiwan and Russia. The results were presented at the American Society of Nephrology (ASN) Kidney Week 2018, San Diego, California, US.
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
Pressmeddelanden • Okt 23, 2018 08:09 CEST
AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly.
AstraZeneca to present new data demonstrating breadth of research portfolio in renal disease at ASN Kidney Week 2018
Pressmeddelanden • Okt 22, 2018 08:10 CEST
AstraZeneca will present new research spanning the Company’s Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, 23-28 October 2018.
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Pressmeddelanden • Okt 21, 2018 16:46 CEST
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced detailed results from the Phase III SOLO-1 trial testing Lynparza (olaparib) tablets as a maintenance treatment for patients with newly-diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
New data on mechanisms of acquired resistance after 1st-line Tagrisso in NSCLC support initiation of ORCHARD trial to explore post-progression treatment options
Pressmeddelanden • Okt 19, 2018 16:02 CEST
AstraZeneca today presented new data on the mechanisms of acquired resistance from the Tagrisso (osimertinib) pivotal Phase III FLAURA trial during an oral late-breaker abstract session at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease
Pressmeddelanden • Okt 19, 2018 14:24 CEST
AstraZeneca today announced that the CHMP of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms inadult patients with chronic obstructive pulmonary disease (COPD).
Pressmeddelanden • Okt 16, 2018 08:01 CEST
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer.
AstraZeneca presents advances in improving treatment options for ovarian and lung cancer patients at ESMO 2018
Pressmeddelanden • Okt 09, 2018 15:07 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the European Society of Medical Oncology (ESMO 2018) Congress in Munich, Germany, 19-23 October.
Pressmeddelanden • Okt 05, 2018 09:07 CEST
AstraZeneca meddelar i dag att man har anställt Christina Malmberg Hägerstrand i en ny roll som presschef för bolaget i Norden och Baltikum. Hon börjar den 7 januari 2019 och kommer rapportera till Kommunikationsdirektör Jacob Lund.
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
Pressmeddelanden • Sep 25, 2018 14:21 CEST
Results from the Phase III PACIFIC trial were published simultaneously in the New England Journal of Medicine, showing Imfinzi (durvalumab) significantly improved OS, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32% (HR 0.68, 99.73% CI 0.47-0.997; p=0.0025).
Pressmeddelanden • Sep 25, 2018 08:02 CEST
Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolic Diseases, at AstraZeneca said: “We are pleased with this positive recommendation for Bydureon and what it means for patients with type-2 diabetes with a wide range of cardiovascular risk. Our pursuit of this label is based on our strong belief in the clinical value the EXSCEL data brings to physicians and patients.”